Hypha's Q1 2023 newsletter

No images? Click here

Hypha Discovery 

What's New Q1 2023

Focus Feature - Recombinant Metabolising Enzymes

Recombinant enzymes are a valuable tool for making metabolites. If you're a PolyCYPs user, then you'll be familiar with the screening kits we have available.  

We have over 100 isoforms in our PolyCYPs platform which are available for testing at Hypha. The Recombinant Technologies team have been busy exemplifying additional capability such as one new PolyCYP which catalyses a hydroxylation reaction to a pirfenidone metabolite at 60% conversion, matching to the human CYP1A2 product. PolyCYP 609 is quite a selective CYP compared to some of the more promiscuous isoforms in the kit, but has been shown to also metabolise 7-ethoxycoumarin and celecoxib.

Phase II capability of some new recombinant microbial UGTs adds to the tools available for making glucuronides and glycosides. 

We undertake projects for clients using a variety of recombinant enzymes, in addition to the other biotransformation tools and chemical synthesis capabilities we have in house.

More about recombinant enzymes

If you'd like to try out our PolyCYPs kits, or are interested in discussing a metabolite project, just reply to this email or contact us through our website.

 

We love client feedback

From a US client about some structure elucidation work we did using cryoprobe NMR, using only 10s of micrograms of material:
“The structure elucidation work Hypha undertook has been very important and helped us to understand what is going on in our experiments with clarity. Additionally, an excellent demonstration of the capability of your team using small amounts of material. We will be in touch again if we have similar projects.”

Contact us
 

Read our latest blog

Our “Metabolite Tales” blogs are science-focused articles on interesting aspects around metabolism and medicinal chemistry in drug discovery and development.

Metabolism of 2022 FDA approved small molecule drugs – Part 1

In Part 1 of this blog on metabolism of small molecules approved by the FDA in 2022, we look at the trends, and whether CYP3A4 still rules.

 

Other blog articles

Have a look at the blog articles we published last year here.

 

There’s more

If you're interested in keeping up with what's happening at Hypha Discovery, follow us on LinkedIn for regular updates.

 
WebsiteTwitterLinkedIn
 
  Tweet 
  Share 
  Forward 

Hypha Discovery

154B Brook Drive, Milton Park,

Abingdon, OX14 4SD, UK

www.hyphadiscovery.com

Email: enquiries@hyphadiscovery.com

You receive Hypha's newsletters quarterly.

Unsubscribe